Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of $17.09 billion. The enterprise value is $14.35 billion.
| Market Cap | 17.09B |
| Enterprise Value | 14.35B |
Important Dates
The next estimated earnings date is Wednesday, November 5, 2025.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 61.50 million shares outstanding. The number of shares has decreased by -3.37% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 61.50M |
| Shares Change (YoY) | -3.37% |
| Shares Change (QoQ) | -3.04% |
| Owned by Insiders (%) | 1.12% |
| Owned by Institutions (%) | 50.95% |
| Float | 60.81M |
Valuation Ratios
The trailing PE ratio is 1.28 and the forward PE ratio is 16.12.
| PE Ratio | 1.28 |
| Forward PE | 16.12 |
| PS Ratio | 4.69 |
| Forward PS | 2.01 |
| PB Ratio | 3.22 |
| P/TBV Ratio | 5.35 |
| P/FCF Ratio | 15.67 |
| P/OCF Ratio | 15.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.81, with an EV/FCF ratio of 13.15.
| EV / Earnings | 10.47 |
| EV / Sales | 3.94 |
| EV / EBITDA | 10.81 |
| EV / EBIT | 11.26 |
| EV / FCF | 13.15 |
Financial Position
The company has a current ratio of 6.22, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.22 |
| Quick Ratio | 6.20 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.11 |
| Debt / FCF | 0.14 |
| Interest Coverage | 49.22 |
Financial Efficiency
Return on equity (ROE) is 28.12% and return on invested capital (ROIC) is 15.86%.
| Return on Equity (ROE) | 28.12% |
| Return on Assets (ROA) | 13.26% |
| Return on Invested Capital (ROIC) | 15.86% |
| Return on Capital Employed (ROCE) | 21.84% |
| Revenue Per Employee | $1.36M |
| Profits Per Employee | $511,147 |
| Employee Count | 2,682 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 21.91 |
Taxes
In the past 12 months, Genmab has paid $182.81 million in taxes.
| Income Tax | 182.81M |
| Effective Tax Rate | 11.77% |
Stock Price Statistics
The stock price has increased by +0.98% in the last 52 weeks. The beta is 0.80, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | +0.98% |
| 50-Day Moving Average | 23.16 |
| 200-Day Moving Average | 21.38 |
| Relative Strength Index (RSI) | 78.02 |
| Average Volume (20 Days) | 1,395,510 |
Short Selling Information
The latest short interest is 3.41 million, so 0.56% of the outstanding shares have been sold short.
| Short Interest | 3.41M |
| Short Previous Month | 3.59M |
| Short % of Shares Out | 0.56% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.04 |
Income Statement
In the last 12 months, Genmab had revenue of $3.65 billion and earned $1.37 billion in profits. Earnings per share was $21.62.
| Revenue | 3.65B |
| Gross Profit | 3.45B |
| Operating Income | 1.27B |
| Pretax Income | n/a |
| Net Income | 1.37B |
| EBITDA | 1.33B |
| EBIT | 1.27B |
| Earnings Per Share (EPS) | $21.62 |
Balance Sheet
The company has $2.90 billion in cash and $148.00 million in debt, giving a net cash position of $2.75 billion or $44.73 per share.
| Cash & Cash Equivalents | 2.90B |
| Total Debt | 148.00M |
| Net Cash | 2.75B |
| Net Cash Per Share | $44.73 |
| Equity (Book Value) | 5.30B |
| Book Value Per Share | 86.21 |
| Working Capital | 3.28B |
Cash Flow
In the last 12 months, operating cash flow was $1.13 billion and capital expenditures -$43.44 million, giving a free cash flow of $1.09 billion.
| Operating Cash Flow | 1.13B |
| Capital Expenditures | -43.44M |
| Free Cash Flow | 1.09B |
| FCF Per Share | $17.74 |
Margins
Gross margin is 94.54%, with operating and profit margins of 34.95% and 37.59%.
| Gross Margin | 94.54% |
| Operating Margin | 34.95% |
| Pretax Margin | 42.60% |
| Profit Margin | 37.59% |
| EBITDA Margin | 36.40% |
| EBIT Margin | 34.95% |
| FCF Margin | 29.91% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.37% |
| Shareholder Yield | 3.37% |
| Earnings Yield | 8.02% |
| FCF Yield | 6.38% |
Analyst Forecast
The average price target for Genmab is $37.60, which is 35.59% higher than the current price. The consensus rating is "Buy".
| Price Target | $37.60 |
| Price Target Difference | 35.59% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 12.52% |
| EPS Growth Forecast (5Y) | 9.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
Genmab has an Altman Z-Score of 9.99 and a Piotroski F-Score of 5.
| Altman Z-Score | 9.99 |
| Piotroski F-Score | 5 |